Kinney Horn - Aug 10, 2021 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role
CHIEF BUSINESS OFFICER
Signature
/s/ John B. Moriarty, Jr., Attorney-in-Fact
Stock symbol
OLMA
Transactions as of
Aug 10, 2021
Transactions value $
-$124,141
Form type
4
Date filed
8/11/2021, 06:05 PM
Previous filing
Jul 13, 2021
Next filing
Sep 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OLMA Common Stock Options Exercise $10.8K +5.25K +293.35% $2.06* 7.04K Aug 10, 2021 Direct
transaction OLMA Common Stock Sale -$133K -5.19K -73.73% $25.70 1.85K Aug 10, 2021 Direct F1, F2
transaction OLMA Common Stock Sale -$1.57K -60 -3.24% $26.17 1.79K Aug 10, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OLMA Stock Option (Right to Buy) Options Exercise $0 -5.25K -2.86% $0.00 179K Aug 10, 2021 Common Stock 5.25K $2.06 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F2 The weighted average sale price for the transaction reported was $25.70, and the range of prices were between $25.11 and $26.10. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.